Levo-Leucovorin

DRUG3 trials

Sponsors

Fujian Cancer Hospital

Conditions

Gastric CancerGastric Cancer Stage IV

Phase 1

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

RecruitingNCT05319639

Fujian Cancer HospitalGastric Cancer Stage IV

Start: 2023-02-16End: 2025-12-31Target: 51Updated: 2025-02-27

Phase 2

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

Not yet recruitingNCT06197438

Fujian Cancer HospitalGastric Cancer

Start: 2024-01-01End: 2025-04-01Target: 36Updated: 2024-01-09

Phase 3

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

RecruitingNCT06793917

Fujian Cancer HospitalGastric Cancer

Start: 2025-06-07End: 2029-04-01Target: 269Updated: 2025-07-20

Related Papers

SYLT-030: Efficacy and safety of tislelizumab plus mFOLFOX6 versus tislelizumab plus POF (paclitaxel + mFOLFOX6) as first-line therapy for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): A multicenter, open-label, randomized phase III trial.

Journal of Clinical Oncology2026-01-10

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin, and 5-FU/levoleucovorin) as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Update from a single-arm, open-label phase II trial (SYLT-023).

Journal of Clinical Oncology2026-01-10

Tislelizumab (Tisle) combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): OS analysis results of the SYLT-023.

Journal of Clinical Oncology2025-01-27

Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023).

Journal of Clinical Oncology2024-01-20